Mayo Clinic Cancer Center Administration's function is to facilitate the mission of the Mayo Clinic Cancer Center (MCCC) in providing administrative management and centralized services that support the Center Director, Senior Leadership, Program Leaders, Shared Resource Directors and members of the Cancer Center. Cancer Center Administration (CCA) actively participates in the planning, implementation and evaluation of programmatic and shared resource activities across MCCC's three campuses. CCA also provides administrative leadership for key MCCC initiatives including efforts to bolster minority accrual to clinical trials, address health disparities, enhance integration and optimize resource utilization and performance. Specific CCA responsibilities include: ? Financial management of all Cancer Center and CCSG funds/accounts; ? Shared resource oversight; ? Design, development and implementation of Cancer Center policies and procedures; ? Management information systems necessary to fulfill intra- and extra-institutional reporting requirements, including Standard Cancer Center Information; ? Coordination of internal funding opportunities; ? Facilitation and management of planning and evaluation activities including the MCCC's External Advisory Committee and retreats; ? Coordination of MCCC committees; ? Oversight of MCCC communications strategies; ? Coordination of MCCC activities within the framework of a 3-site, matrix center consistent with institutional policy and regulatory requirements;and ? Principal liaison between the MCCC and other Mayo Clinic research, practice, education, administration and support services units, activities and functions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-38S1
Application #
8533256
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$27,830
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications